Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B18a00e6333930628cb632c6dd590325c> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B18a00e6333930628cb632c6dd590325c NCIT_P378 "NCI" @default.
- B18a00e6333930628cb632c6dd590325c type Axiom @default.
- B18a00e6333930628cb632c6dd590325c annotatedProperty IAO_0000115 @default.
- B18a00e6333930628cb632c6dd590325c annotatedSource NCIT_C98831 @default.
- B18a00e6333930628cb632c6dd590325c annotatedTarget "An orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Brigatinib binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. This leads to the inhibition of ALK kinase and EGFR kinase, disrupts their signaling pathways and eventually inhibits tumor cell growth in susceptible tumor cells. In addition, AP26113 appears to overcome mutation-based resistance. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. EGFR is overexpressed in a variety of cancer cell types." @default.